<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02428101</url>
  </required_header>
  <id_info>
    <org_study_id>master(No.38)</org_study_id>
    <nct_id>NCT02428101</nct_id>
  </id_info>
  <brief_title>Oxaliplatin - Induced Peripheral Neuropathy in Patients With Gastrointestinal Tract Cancer</brief_title>
  <official_title>Relation of Genetic Polymorphism of ABCG2 Gene And Occurrence of Oxaliplatin - Induced Peripheral Neuropathy in Patients With Gastrointestinal Tract Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine DNA from Gastrointestinal Tract of cancer patients treated with
      oxaliplatin to look for a variation (mutation) of the ABCG2 gene that may lead to
      drug-induced peripheral neuropathy in certain patients.

      The DNA will be extracted from patients' blood samples and are analyzed for the ABCG2 single
      nucleotide polymorphism (G34A - rs2231137 ,C421A-rs2231142 , A/A -rs3114018 genotypes) and
      correlated with peripheral neuropathy grades.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacogenetic analysis/genotyping :

      Genotyping is conducted via High Resolution Melting (HRM) TECHNIQUE, To confirm the
      genotyping results, the Polymerase chain reaction (PCR) product of the samples will be
      examine via direct sequencing using 3500 Genetic analyzer from ThermoFisher (applied
      biosystem) at three ABCG2 loci using the following PCR primers:

      1-ABCG2 G34A - rs2231137

      Forward :

      5'-TGC AAT CTC ATT TAT CTG GAC TA-'3

      Reverse :

      5'-AAT GCC TTC AGG TCA TTG GA-'3

      -Annealing temp :57 -Product size : 163

      2- ABCG2 C421A - rs2231142

      Forward :

      5'- GATGGGCACTCTGACGGT -'3

      Reverse :

      5'- GACCCTGTTAATCCGTTCGTTT-'3

      -Annealing temp : 59 -Product size : 103

      3- ABCG2 A/A - rs3114018

      Forward :

      5'- TGATGTTCCTTCAGCCACTG-'3

      Reverse :

      5'-TTGTGGAAACCTCACAAAAGTG-'3

      - Annealing temp : 59 - Product size : 124
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of single nucleotide polymorphisms of ABCG2 gene (G34A - rs2231137 ,C421A-rs2231142 and A/A -rs3114018 genotypes) with peripheral neuropathy grades, using the National Cancer Institute Common Toxicity Criteria (NCI-CTCAE)</measure>
    <time_frame>After 6 cycles of chemotherapy (each cycle is15 days), for six months</time_frame>
    <description>Peripheral Neuropathy Toxicity will be assessed every cycle for six months using the National Cancer Institute Common Toxicity Criteria (NCI-CTCAE). Patients will be assigned to 4 groups according to the grades of neuropathy.</description>
  </primary_outcome>
  <enrollment type="Actual">80</enrollment>
  <condition>Gastrointestinal Tract Cancer</condition>
  <condition>Peripheral Neuropathy</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Gastrointestinal tract (GIT) Cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gastrointestinal Tract Cancer patients treated with Oxaliplatin-containing
             chemotherapy

          -  Measurable disease

          -  Age of 18 years to 80 years

        Exclusion Criteria:

          -  Pregnant women

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to Oxaliplatin.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Neurologic disease or patients with disease impairing the neurologic function
             affecting
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inas M Moukhtar Ahmed, B.pharma</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Pharmacy, Ain Shams Universty</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lamia M El Wakeel, Assoc. Prof</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Pharmacy, Ain Shams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdel Hady A Abdel Wahab, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Biochemistry &amp; Molecular biology,Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amr S Saad, Assoc. Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Clinical Oncology, Ain Shams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raafat R Abdel-Malek, Assoc. Prof</last_name>
    <role>Study Chair</role>
    <affiliation>clinical oncology, cairo university</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ain Shams University hospitals</name>
      <address>
        <city>Cairo</city>
        <state>Abbasia</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2015</study_first_submitted>
  <study_first_submitted_qc>April 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2015</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Inas M Ahmed, PH</investigator_full_name>
    <investigator_title>African Union,organization St. Abbsia, Cairo, Egypt</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

